Can a lower dose of this leukemia drug keep the disease at bay?
Disease control
ENROLLING_BY_INVITATION
This study looks at whether reducing the dose of the drug olverembatinib can still control chronic myeloid leukemia in patients who have already responded well to treatment. About 100 adults with chronic or accelerated phase CML will switch to a lower dose (20 mg every other day)…
Sponsor: Qian Jiang • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC